Anest. intenziv. Med. 2026;37(3):183-185 | DOI: 10.36290/aim.2026.015

Stanovisko k perioperačnímu podávání SGLT2 inhibitorů a GLP‑1 receptorových agonistů u dospělých pacientůReports from professional societies

Černý V., Beneš J., Vymazal T., Bláha J., Tesařík R., Štourač P., Žižka J., Gabrhelík T.

Received: April 17, 2026; Accepted: April 17, 2026; Published: October 14, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Černý V, Beneš J, Vymazal T, Bláha J, Tesařík R, Štourač P, et al.. Stanovisko k perioperačnímu podávání SGLT2 inhibitorů a GLP‑1 receptorových agonistů u dospělých pacientů. Anest. intenziv. Med. 2026;37(3):183-185. doi: 10.36290/aim.2026.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 40 CZK (1.7 EUR)
    will be unlocked 14.10.2027

    References

    1. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]. Silver Spring (MD): FDA; 2015 [updated 2022 Mar 16; cited 2026 Jul 8]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious.
    2. Kumar S, Bhavnani SP, Goyal P, Rich MW, Krishnaswami A. Preoperative Cessation of SGLT2i [Internet]. Washington (DC): American College of Cardiology; 2022 Oct 7 [cited 2026 Jul 8]. Available from: https://www.acc.org/Latest-in-Cardiology/Articles/2022/10/07/17/21/Preoperative-Cessation-of-SGLT2i.
    3. American Society of Anesthesiologists. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-like Peptide-1 (GLP-1) Receptor Agonists [Internet]. Schaumburg (IL): ASA; 2023 Jun 29 [cited 2026 Jul 8]. Available from: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative.
    4. American Society of Anesthesiologists. Most Patients Can Continue Diabetes, Weight Loss GLP-1 Drugs Before Surgery, Those at Highest Risk for GI Problems Should Follow Liquid Diet Before Procedure: New Multi-Society Clinical Practice Guidance Released [Internet]. Schaumburg (IL): ASA; 2024 Oct 29 [cited 2026 Jul 8]. Available from: https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance.
    5. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al.; American Gastroenterological Association; American Society for Metabolic and Bariatric Surgery; American Society of Anesthesiologists; International Society of Perioperative Care of Patients with Obesity; Society of American Gastrointestinal and Endoscopic Surgeons. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clin Gastroenterol Hepatol. 2025 Nov;23(12):2083-2085. doi: 10.1016/j.cgh.2024.10.003. Go to original source... Go to PubMed...
    6. Oprea AD, Ostapenko LJ, Sweitzer B, Selzer A, Irizarry-Alvarado JM, Hurtado Andrade MD, et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2025 Jul;135(1):48-78. doi: 10.1016/j.bja.2025.04.001. Go to original source... Go to PubMed...
    7. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes - 2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S339-S355. doi: 10.2337/dc26-S016. Go to original source...
    8. Oprea AD, Mohamed B, Hepner DL, Auron M, Richman DC, Umpierrez GE, et al. Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2026 Jun;136(6):1776-1799. doi: 10.1016/j.bja.2026.02.031. Go to original source... Go to PubMed...
    9. Chen A, Zhao K, Ceban F, Nabipoor M, Englesakis M, Chung F, et al. Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies. Can J Anesth/J Can Anesth. 2026;73:345-356. doi: 10.1007/s12630-026-03114-6. Go to original source... Go to PubMed...
    10. Boudreau C, Couture M, Rousseau-Saine N, Laferrière-Langlois P, Roy-Renaud É, Burey J, et al. Residual gastric content after holding of glucagon-like peptide-1 receptor agonists before elective surgery: a cross-sectional study - the RESIDUAL study. BMC Anesthesiol. 2026 Jun 10. doi: 10.1186/s12871-026-03999-2. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.